Request Demo

Last update 08 May 2025

TNFAIP6

Last update 08 May 2025

Basic Info

Synonyms

Hyaluronate-binding protein, TNF alpha induced protein 6, TNF alpha-induced protein 6

+ [6]

Introduction

Major regulator of extracellular matrix organization during tissue remodeling (PubMed:15917224, PubMed:18042364, PubMed:26823460). Catalyzes the transfer of a heavy chain (HC) from inter-alpha-inhibitor (I-alpha-I) complex to hyaluronan. Cleaves the ester bond between the C-terminus of the HC and GalNAc residue of the chondroitin sulfate chain in I-alpha-I complex followed by transesterification of the HC to hyaluronan. In the process, potentiates the antiprotease function of I-alpha-I complex through release of free bikunin (PubMed:15917224, PubMed:16873769, PubMed:20463016). Acts as a catalyst in the formation of hyaluronan-HC oligomers and hyaluronan-rich matrix surrounding the cumulus cell-oocyte complex, a necessary step for oocyte fertilization (PubMed:26468290). Assembles hyaluronan in pericellular matrices that serve as platforms for receptor clustering and signaling. Enables binding of hyaluronan deposited on the surface of macrophages to LYVE1 on lymphatic endothelium and facilitates macrophage extravasation. Alters hyaluronan binding to functionally latent CD44 on vascular endothelium, switching CD44 into an active state that supports leukocyte rolling (PubMed:15060082, PubMed:26823460). Modulates the interaction of chemokines with extracellular matrix components and proteoglycans on endothelial cell surface, likely preventing chemokine gradient formation (PubMed:27044744). In a negative feedback mechanism, may limit excessive neutrophil recruitment at inflammatory sites by antagonizing the association of CXCL8 with glycosaminoglycans on vascular endothelium (PubMed:24501198). Has a role in osteogenesis and bone remodeling. Inhibits BMP2-dependent differentiation of mesenchymal stem cell to osteoblasts (PubMed:16771708, PubMed:18586671). Protects against bone erosion during inflammation by inhibiting TNFSF11/RANKL-dependent osteoclast activation (PubMed:18586671).

Drugs associated with TNFAIP6

WO2022157181

Patent Mining

Target

TNFAIP6

Mechanism-

Active Org.

The University of Manchester

Originator Org.

The University of Manchester

Active Indication

Hematologic Diseases [+3]

Inactive Indication-

Drug Highest PhaseDiscovery

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with TNFAIP6

100 Translational Medicine associated with TNFAIP6

0 Patents (Medical) associated with TNFAIP6

831

Literatures (Medical) associated with TNFAIP6

31 Dec 2025·Annals of Medicine

A diagnostic signatures for intervertebral disc degeneration using TNFAIP6 and COL6A2 based on single-cell RNA-seq and bulk RNA-seq analyses

Article

Author: Shen, Jun-Kang ; Li, Zuo-Wei ; Li, Ming-Hua ; Song, Hong-Mei ; Wu, Chun-Gen ; Huang, Qin

OBJECTIVESIntervertebral disc degeneration (IVDD) is a prevalent degenerative condition associated with a high incidence rate of low back pain and disability. This study aimed to identify potential biomarkers and signaling pathways associated with IVDD.METHODSBiomarkers were discerned through bulk-RNA and single-cell RNA sequencing (scRNA-Seq) investigations of IVDD cases from the Gene Expression Omnibus (GEO) database. Following this, two central genes were identified. Furthermore, gene set enrichment analysis (GSEA) and receiver operating characteristic (ROC) curve analysis were conducted. The transcriptional factor (TF) derived from nucleus pulposus (NP) cells was examined through the DoRothEA R package. RT-qPCR and IHC techniques were employed to confirm the expression of the two hub genes and their associated genes in tissue samples.RESULTSThe proteins Tumor necrosis factor-inducible gene 6 protein (TNFAIP6) and collagen VI-α2 (COL6A2) were frequently analyzed using a combination of DEGs from datasets GSE70362, GSE124272, and scRNA-seq. Examination of gene expression across multiple datasets indicated significant differences in TNFAIP6 and COL6A2 levels in IVDD compared to control or normal groups (p < 0.05). These two central genes demonstrated strong diagnostic utility in the training cohort and reliable predictive value in the validation datasets. Our study verified the potential role of ZEB2 as a TF in regulating two key genes associated with IVDD. Furthermore, qPCR and IHC confirmed elevated expression levels of the hub genes and transcription factor.CONCLUSIONWe identified biomarkers, specifically TNFAIP6 and COL6A2, that have the potential to predict disease activity and aid in the diagnosis of IVDD.

31 Dec 2025·Animal Cells and Systems

Adaptation responses to salt stress in the gut of Poecilia reticulata

Article

Author: Lee, Hyerim ; Yi, Sun-Ju ; Kim, Kyunghwan ; Yeo, Hyunjae ; Kang, Keunsoo ; Park, Jihye

Osmoregulation is essential for the survival of aquatic organisms, particularly teleost fish facing osmotic challenges in environments characterized by variable salinity. While the gills are known for ion exchange, the intestine's role in water and salt absorption is gaining attention. Here, we investigated the adaptive responses of the intestine to salinity stress in guppies (Poecilia reticulata), observing significant morphological and transcriptomic alterations. Guppies showed superior salt tolerance compared to zebrafish (Danio rerio). Increasing salinity reduced villus length and intestinal diameter in guppies, while zebrafish exhibited damage to villus structure and loss of goblet cells. Transcriptomic analysis identified key genes involved in osmoregulation, tissue remodeling, and immune modulation. Upregulated genes included the solute carrier transporters slc2al and slc3al, which facilitate ion and water transport, as well as a transcription factor AP-1 subunit and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta, both of which participate in tissue repair and growth responses. In contrast, many genes related to the innate immune system (such as Tnfaip6) were downregulated, suggesting a shift toward the prioritization of osmoregulatory functions over immune responses. Interestingly, the differential expression of adaptation genes was linked to variations in epigenetic modifications and transcription factor activity. Transcription factors crucial for adapting to salt stress, such as bhlhe40, cebpd, and gata6, were progressively upregulated in guppies but remained downregulated in zebrafish. Our findings highlight the intricate mechanisms of adaptation to salinity stress in P. reticulata, providing insights into osmoregulatory mechanisms involving the intestine in aquatic organisms.

01 Jul 2025·Theriogenology

SETD2 regulates oocytes in vitro maturation through histone methylation and maternal mRNA degradation in yak

Article

Author: Wang, Meng ; Yang, Shanshan ; Ma, Wenbin ; Zhang, Hui ; Pan, Yangyang ; Ma, Rui ; Wang, Jinglei ; Cui, Yan ; Huang, Jiaxin ; Yu, Sijiu

In vitro maturation (IVM) of oocytes is a vital aspect of assisted reproductive technology (ART), and its proper application can enhance reproductive efficiency. However, owing to the scarcity of research on the IVM of yak oocytes, its application in yak breeding remains underexplored. Therefore, in this study, we conducted high-throughput mRNA sequencing of immature and mature yak oocytes, which revealed transcriptomic changes during the IVM process in this unique high-altitude domesticated animal. Transcriptomic analysis also identified the histone methyltransferase SET domain-containing 2 (SETD2) as a key factor associated with post-translational modifications during oocyte maturation. To determine the role of SETD2 in oocytes, we employed the SETD2 inhibitor EZM0414 during oocyte maturation. Inhibition of SETD2 resulted in a significant reduction in histone methylation levels, lower oocyte maturation rate in vitro, and suppression of maternal mRNAs degradation suppression (P < 0.05). These findings indicated that SETD2 modulates oocyte maturation by regulating histone methylation and maternal mRNAs degradation. Furthermore, suppression of SETD2 markedly reduced the expression of oocyte secretion-related proteins (TSG6 and GDF9) and cumulus expansion-related protein (PTGS2), demonstrating that oocyte secretion and cumulus expansion were positively correlated with SETD2. Overall, our findings establish SETD2 as an essential regulator of yak oocyte maturation via histone methylation and maternal mRNAs degradation.

News (Medical) associated with TNFAIP6

05 Mar 2021

·www.biospace.com

TSG6 Antibody Research Receives a Nudge from Oncology Treatment Applications: Fact.MR

Rising burden of various types of cancers and the consequent increase in mortality rates is compelling clinicians to incorporate advanced diagnostics and treatment approaches, widening the scope for antibody treatment Fact.MR Rockville: As the global burden of cancer increases, advanced therapeutic approaches are being investigated by key healthcare experts. This trend is likely to widen the berth for the TSG6 antibody market in forthcoming years. Award winning market research company Fact.MR is currently working on an exhaustive study concerning key application areas of TSG6 antibodies, with enhanced scope for future research across North America, Europe and the Asia-Pacific respectively. According to the National Cancer Institute, an estimated 1.8 million new cancer cases were detected in the United States alone, with a perceived fatality rate of over 600,000 individuals. Prostate, lung and colorectal cancers accounted for nearly 43% of all cancers diagnosed in men as of 2020, with new rates averaging at 442.4 per 100,000 men and women annually. Consequently, healthcare providers are looking to leverage advanced therapeutic approaches, leading to extensive research and development. Over the years, a host of manufacturers have dominated the TSG6 antibody landscape, offering different combinations aimed at streamlining oncology treatment. For instance, Biorbyt recently released the LYPLA3 antibody codenamed orb185108-Biotin, a rabbit-derived biotin antibody for applications across ELISA, ICC and IHC-P testing respectively. Similarly, Fitzgerald International manufactures primary antibodies, such as the Bradykinin Receptor Antibody and BT CRY2A Antibody. “Accelerating research for discovering advanced therapeutic approaches to numerous chronic and infectious ailments is heightening scope for TSG6 antibody research, with manufacturers experimenting with different formulations to introduce novel treatment solutions,” remarks the Fact.MR analyst. Request a report sample to gain comprehensive insights at Key Takeaways from Fact.MR’s TSG6 Antibody Market Report By product, above 95% TSG6 antibodies to experience high growth through the forecast period Biopharmaceutical companies to remain primary TSG6 antibody end-users, owing to increasing clinical trials to fund advanced research US to remain a potential market, with the FDA approving 79 therapeutic monoclonal antibodies as of 2019 Proliferating antibody research for chronic & infectious ailments to spearhead sales across the UK Germany & France to experience high growth amid rising cancer research funding Opportunities abound across the Asia-Pacific: China & India to emerge as key revenue ecosystems TSG6 Antibody Market- Prominent Drivers Rising cancer research initiatives for identifying tumor necrosis is expanding TSG6 antibody sales The market is receiving traction amid rising demand across immunochemistry, western blotting and immunofluorescence Clinicians are investigating additional application areas such as lung disorders treatment TSG6 Antibody Market- Key Restraints Shorter response to antibody therapy could lead to inaccurate conclusions, affecting the outcome Perceived side effects such as anaphylaxis and low blood pressure to limit TSG6 antibody based treatments Discover more about the TSG6 antibody market with figures, data tables and the table of contents. You will also find detailed market segmentation on Competitive Landscape Key TSG6 antibodies providers profiled by Fact.MR include Thermo Fisher Scientific, Abbexa Ltd., Aviva Systems Biology Corporation, Boster Biological Technology, Genetex, Biorbyt, Fitzgerald Industries International, Lifespan Biosciences, Origene and US Biological among others. Primary expansion strategies include collaborations, acquisitions, research & development and new product launches. In February 2021, Thermo Fisher Scientific successfully completed the acquisition of Mesa Biotech Inc., a privately held point-of-care molecular diagnostics company. The acquisition was carried out to acquire its Accula PCR-based testing system for infectious diseases. In the long-run, the acquisition is likely to also widen Thermo Fisher’s scope across chronic disease diagnostics, which will enhance its TSG6 antibody portfolio as well. Boster Biological Technology is another prominent player, manufacturing the PicobandTM Anti-TSG6/TNFAIP6 Antibody, a rabbit-based IgG polyclonal antibody for tumor necrosis factor-inducible gene 6 protein detection. It consists of a synthetic peptide corresponding to a sequence at the N-terminus of human TSG6. More Insights on the Global TSG6 Antibody Market In its latest report, Fact.MR offers unbiased analysis of the globalTSG6 antibody market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of type (above 90%, above 95%, above 99% & others) and application (biopharmaceutical companies, hospitals, bioscience research institutions and others) across seven regions (North America, Latin America, Western Europe, Eastern Europe, Japan, APEJ and Middle East & Africa) Get Customization on this Report for Specific Research Solutions Explore Fact.MR’s Coverage on the Healthcare Domain Benign Prostatic Hyperplasia Treatment Market: The study on the benign prostatic hyperplasia (BPH) treatment market is an exclusive report published by Fact.MR, which brings to the fore crucial parameters that have been influencing the growth of the market. This exclusive study provides incisive insights regarding recent developments in the benign prostatic hyperplasia treatment market, analyzing both historical as well as future data. Asthma Treatment Market: The study on the asthma treatment market is an exclusive study, which has been recently added to the broad report repository of Fact.MR. The study brings to light crucial influencers that have been influencing the growth of the asthma treatment market. This comprehensive study offers analytical insights pertaining to the recent developments in the asthma treatment market. Canes and Crutches Market: The study on the canes and crutches market is an exclusive report published by Fact.MR, which brings to the fore crucial parameters that are driving the growth of the market. This exclusive study provides incisive insights regarding recent developments in the canes and crutches market, by analyzing the historical as well as future data projections. About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner. Contact: Sudip Saha US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583

AntibodyAcquisitionCollaborate

Analysis

Perform a panoramic analysis of this field.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

TNFAIP6

Basic Info

Related

Analysis